<DOC>
	<DOC>NCT00323050</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of the Hib-MenC conjugate vaccine when given to healthy subjects aged 13 to 14 months who were primed with three doses of Hib-MenC compared to a booster dose of Infanrix hexa given to subjects primed with three doses of Infanrix hexa and Meningitec.</brief_summary>
	<brief_title>Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects</brief_title>
	<detailed_description>The study is open and Infanrix hexa will serve as active control. Subjects will receive one vaccine dose of either Hib-MenC or Infanrix hexa, and will have 2 blood samples taken: before and one month after vaccination. Subjects who will receive a booster dose of Hib-MenC were primed with 3 doses of Infanrix penta + Hib-MenC or 2 doses of NeisVac-C and Infanrix hexa / Infanrix IPV/Hib.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criteria: Healthy male or female between, and including, 13 and 14 months of age Having participated in the primary vaccination study 217744/097. Exclusion criteria: Previous vaccination against OR history of OR known exposure to diphtheria, tetanus, pertussis, hepatitis B, polio, H. influenzae type b (Hib) and/or meningococcal serogroup C disease except if within the framework of study 217744/097 Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection A family history of congenital or hereditary immunodeficiency History of any neurologic disorders or seizures</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>